GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tvardi Therapeutics Inc (LTS:0HTC) » Definitions » Additional Paid-In Capital

Tvardi Therapeutics (LTS:0HTC) Additional Paid-In Capital : £582.39 Mil(As of Mar. 2025)


View and export this data going back to 2025. Start your Free Trial

What is Tvardi Therapeutics Additional Paid-In Capital?


Tvardi Therapeutics's quarterly additional paid-in capital increased from Mar. 2024 (£0.00 Mil) to Sep. 2024 (£0.76 Mil) and increased from Sep. 2024 (£0.76 Mil) to Mar. 2025 (£582.39 Mil).

Tvardi Therapeutics's annual additional paid-in capital increased from . 20 (£0.00 Mil) to Dec. 2022 (£0.37 Mil) and increased from Dec. 2022 (£0.37 Mil) to Dec. 2023 (£0.60 Mil).

Tvardi Therapeutics Additional Paid-In Capital Historical Data

The historical data trend for Tvardi Therapeutics's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Tvardi Therapeutics Additional Paid-In Capital Chart

Tvardi Therapeutics Annual Data
Trend Dec22 Dec23
Additional Paid-In Capital
0.37 0.60

Tvardi Therapeutics Quarterly Data
Dec22 Dec23 Mar24 Sep24 Mar25
Additional Paid-In Capital 0.37 0.60 - 0.76 582.39

Tvardi Therapeutics Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Tvardi Therapeutics Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Tvardi Therapeutics's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Tvardi Therapeutics Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Tvardi Therapeutics Inc (LTS:0HTC) » Definitions » Additional Paid-In Capital
Comparable Companies
SGMO INBX ACTU HURA DMAC INMB AARD TVGN RGLS KRRO VRTX ASX:CSL REGN XKRX:207940 XBRU:ARGX ALNY XBRU:UCB ONC BNTX XKRX:068270
Traded in Other Exchanges
TVRD:USA 69C:Germany
Address
3 Sugar Creek Center boulevard, Suite 525, Sugar Land, TX, USA, 77478
Website
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.

Tvardi Therapeutics Headlines

No Headlines